Sponsors (4)
The bill expands access to long‑acting injectable medications, related services, and clinician training—improving treatment capacity and transparency—while raising federal costs, adding reporting burdens, and risking diversion of resources from other treatment options.
People with substance use disorders and serious mental illness gain clearer access to FDA‑approved long‑acting injectable medications plus associated clinical services including authorized lab testing and supportive counseling.
Clinicians, hospitals, and treatment programs receive training on long‑acting injectable medication use, increasing system capacity to deliver these treatments.
Congress and the public get annual outcome reports on the program, improving transparency and oversight of federally funded activities.
People who prefer or need non‑injectable treatment modalities could see resources shifted away from other forms of care, potentially harming some patients' outcomes.
Expanding covered services (injectables, testing, training) could increase federal grant spending or require reallocation of existing funds, affecting taxpayers and state budgets.
Annual clinician‑assessed outcome reporting creates additional administrative burden for HHS, grantees, and health systems to collect and submit data.
Based on analysis of 2 sections of legislative text.
Makes long‑acting injectable medications, lab testing, counseling, and training explicitly authorized services under the SUD/SMI grant program and requires annual outcome reports to Congress.
Official title: To amend the Public Health Service Act to authorize the Secretary of Health and Human Services to address priority substance use disorder and serious mental illness treatment needs through long-acting injectable medications, and for other purposes.
Introduced June 17, 2025 by Neal Patrick Dunn · Last progress June 17, 2025
Authorizes and clarifies grant program services for treating substance use disorders (SUD) and serious mental illness by expressly allowing FDA‑approved long‑acting injectable medications, associated lab testing and counseling, and training plus related clinical services. Requires the Secretary of Health and Human Services to provide Congress with an annual report on program outcomes starting within one year of enactment; the changes apply to grants awarded after the law takes effect.